digital therapeutics

By Aline Noizet 02:16 am April 29, 2020
Dr. Morcillo is the director of internal medicine Hospital Cima Sanitas in Barcelona and the medical director of Sanitas digital hospital. He is an active advocate and user of digital technologies in his daily practice. He will join the HIMSS & Health 2.0 European conference in September as an expert in the session on digital therapeutics. The below Q&A has been edited for length and...
By Dave Muoio 06:00 am April 22, 2020
Less than a week after FDA opened the faucet for digital health products treating psychiatric conditions during the COVID-19 health crisis, Akili has fast-tracked and released its approval-pending digital therapeutic for children with ADHD. Now known as Endeavor and flanked by a symptom tracker and caretaker support line, the video game-like app will be provided at no cost for a limited time to...

Credit: Kaiku Health

By Sophie Porter 02:14 am April 15, 2020
Digital oncological therapeutics company Kaiku Health has developed a symptom monitoring system for patients with coronavirus to be used by Geneva University Hospitals (HUG). The platform will assist HUG in triaging patients who suspect they have the virus or who have already been diagnosed, both in and out of hospital. WHAT IT DOES Each day patients will fill out a digital report of their...
By Dave Muoio 04:28 pm April 8, 2020
Easy access to (temporarily) free counseling. Consumer telehealth and mail-order prescription services Hims and Hers are dipping into the mental health wellness space. The brands kicked off new anonymized group therapy and guided meditation offerings yesterday, with the therapy sessions led by a licensed mental health practitioner. The group sessions are currently being offered free of charge in...

Credit: SideKick Health

By Tammy Lovell 08:08 am April 1, 2020
Nordic startup SideKickHealth is working with the COVID-19 response team in Iceland to provide its digital therapeutics platform to people who have been diagnosed with the virus. Its platform allows the remote triaging and managing of large numbers of people in isolation, who self-report on a panel of symptoms and measurements via a smartphone app multiple times a day.  Patients are assessed via...
By Dave Muoio 03:53 pm March 26, 2020
Pear Therapeutics announced this morning that Somryst, its prescription digital therapeutic for adults with chronic insomnia, has received marketing authorization from the FDA. The treatment provides cognitive behavioral therapy for insomnia (CBTi) alongside personalized, algorithm-generated sleep restriction recommendations. The digital therapeutic was reviewed through the agency's 510(k)...
By Dave Muoio 02:58 pm March 11, 2020
A CVS Health service designed to help CVS Caremark pharmacy benefit management clients more easily roll out and manage third-party health products has added five new digital health offerings to its lineup. The program – which has also seen a branding change from "Vendor Benefit Management" to "Point Solutions Management" – was first announced last June with only single participating vendor: Big...
By Dave Muoio 07:50 pm February 24, 2020
A full transcript of STARS-ADHD — the pivotal trial of Akili Interactive’s video game-like pediatric attention deficit treatment — has been published in The Lancet Digital Health journal, providing onlookers a clear view of data fueling the digital therapeutic company’s pending FDA submission. The writeup echoes topline findings first unveiled by the company in December 2017: compared to a...
By Dave Muoio 02:00 pm January 15, 2020
Editor's note: The original version of this story claimed that STARS-ADHD Adjunctive enrolled 2016 subjects, instead of 206. We apologize for this error. Digital therapeutic company Akili Interactive has announced the first results of an open-label, multisite pediatric ADHD trial providing some patients with the company’s video game-like treatment alongside a stimulant medication. Called the ...
By Dave Muoio 02:45 pm January 14, 2020
Following news of hardships at Proteus Digital Health, CEO Andrew Thompson has told STAT News that the company is winding down its high-profile $88 million deal with Otsuka Pharmaceutical, and will be pivoting from its current primary focus on mental disorders toward cancers and infectious disease treatments. The pharmaceutical company has now acquired the full license for Proteus’ mental health...